Cartesian Therapeutics (RNAC) Long-Term Investments (2015 - 2025)

Cartesian Therapeutics (RNAC) has reported Long-Term Investments for 11 consecutive years, with $2.0 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Long-Term Investments changed 0.0% year-over-year to $2.0 million; the TTM figure through Sep 2025 stood at $2.0 million (changed 0.0% YoY), while the FY2024 annual figure was $2.0 million, changed 0.0% from the prior year.
• Long-Term Investments held at $2.0 million in Q3 2025 per RNAC's latest filing, from $2.0 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $2.0 million in Q3 2021 and bottomed at $2.0 million in Q3 2021.
• Historically, Long-Term Investments has averaged $2.0 million across 5 years, with a median of $2.0 million in 2021.
• Annual changes were most pronounced in 2021 — Long-Term Investments soared 45.03% — and 2022, when it changed 0.0%.
• Cartesian Therapeutics' Long-Term Investments stood at $2.0 million in 2021, then changed by 0.0% to $2.0 million in 2022, then changed by 0.0% to $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then changed by 0.0% to $2.0 million in 2025.
• Business Quant data shows RNAC's Long-Term Investments at $2.0 million in Q3 2025, $2.0 million in Q2 2025, and $2.0 million in Q1 2025.